Biotech · Private company
Asahi Kasei Therapeutics, AB
Track this companyFree. Adds Asahi Kasei Therapeutics, AB to your Dealase workspace and tells you when its record changes.
Clinical trials51 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- NefeconPhase 3 · Primary IgA NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- Nefecon 16mg dailyPhase 3 · Primary IgA NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- GKT137831Phase 2 · Primary Biliary CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- GKT137831Phase 2 · Type 2 Diabetes Mellitus With Diabetic NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- TARPEYO®IgA NephropathyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA NephropathyPHASE4 · ACTIVE_NOT_RECRUITING · started Dec 17, 2024ClinicalTrials.gov NCT06712407 · fetched Nov 12, 2026
- Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)PHASE3 · COMPLETED · started Nov 17, 2020ClinicalTrials.gov NCT04541043 · fetched Nov 12, 2026
- Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) NephropathyPHASE3 · COMPLETED · started Sep 5, 2018ClinicalTrials.gov NCT03643965 · fetched Nov 12, 2026
- Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.PHASE2 · COMPLETED · started Jun 26, 2017ClinicalTrials.gov NCT03226067 · fetched Nov 12, 2026
- Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and AlbuminuriaPHASE2 · COMPLETED · started Oct 1, 2013ClinicalTrials.gov NCT02010242 · fetched Nov 12, 2026